Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
TG Therapeutics ( (TGTX) ) has provided an update.
On January 14, 2025, TG Therapeutics announced preliminary U.S. net product revenue for BRIUMVI, reporting $103.6 million for Q4 and $310 million for the full year 2024, exceeding expectations. The company also presented its 2025 guidance, targeting $540 million in global revenue, primarily driven by BRIUMVI sales, and outlined development milestones, including trials for subcutaneous administration and further indications for BRIUMVI beyond MS, positioning it as a significant player in the biotechnology sector.
More about TG Therapeutics
TG Therapeutics, Inc. operates in the biotechnology industry, focusing primarily on the development of novel treatments for autoimmune diseases. Their flagship product, BRIUMVI, is a monoclonal antibody targeting CD20-expressing B-cells, used in the management of relapsing forms of multiple sclerosis.
YTD Price Performance: -10.91%
Average Trading Volume: 2,967,166
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $4.5B
See more data about TGTX stock on TipRanks’ Stock Analysis page.
